Gosset Ownership
Public
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Stereotaxis General Information
Stereotaxis has commercialized its Genesis RMN System and related robotic navigation technologies for cardiac ablation. Its systems have been used in over 100,000 patients worldwide. The company recently received FDA clearance for new models and CE mark approval in Europe for its latest products. Clinical use demonstrates improved precision and safety in treating complex arrhythmias with minimally invasive approaches.
Contact Information
Primary Industry
Surgical Medical Devices
Corporate Office
St. Louis, Missouri
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Acutus Medical (collaboration on open platform), My Language Connection (translation/localization partner), various hospital networks globally
Stereotaxis Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Nov 12, 2025 | $4.0M | Completed | Commercial |
To view Stereotaxis's complete valuation and funding history, request access »
Stereotaxis Financial Metrics
Market Cap
$178.9M
Total Revenue
$8.6M
Enterprise Value
$171.0M